Kurkure 2012.

Clinical features and settings	Study period: n.r. Patient population: 22 patients with neuroblastoma and 18F‐FDG‐PET scans and ¹³¹I‐MIBG scans within a time span of three days. Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans between symptoms and index test, between symptoms and reference standard and between index test and reference standard: n.r. Treatment between index test and reference standard: n.r.
Participants	Included patients: 22 children with neuroblastoma and a 18F‐FDG‐PET scan at first diagnosis. Median age: n.r. Sex distribution: n.r. INSS stage: n.r.
Study design	n.r.
Target condition and reference standard(s)	Target condition: newly diagnosed neuroblastoma. Reference standard: n.r.
Index and comparator tests	Index test: 18F‐FDG‐PET scintigraphy. Radiofarmacon: 18F‐FDG‐PET. Dose: n.r. Equipment: n.r. Acquisition protocol: n.r. Acquisition time: n.r. Acquisition duration: n.r. Interfering medication: n.r. Thyroid prophylaxis: n.r. Positive test result: n.r. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Not published in full‐text (as of December 2012), but presented at the SIOP conference 2012. The abstract did not contain relevant results for this review and based on the currently available information it is unclear whether this study fulfills the inclusion criteria for this review. We could not get in contact with the study authors.